Overview
| Product name | Recombinant Human HB-EGF Protein |
|---|
| Catalog No. | RP00754 |
|---|
| Description | Recombinant Human HB-EGF Protein is produced by Human Cells expression system. The target protein is expressed with sequence (Leu20-Leu148) of human HB-EGF (Accession #Q99075) fused with a 6×His tag at the C-terminus. |
|---|
| Bio-Activity | Measured in a cell proliferation assay using Balb3T3 mouse fibroblast cells. The ED50 for this effect is 0.15-0.60 ng/mL, corresponding to a specific activity of 1.67×106~6.67×106 units/mg.
|
|---|
| Purity | > 95% by SDS-PAGE. |
|---|
| Endotoxin | < 1 EU/μg of the protein by LAL method. |
|---|
| Formulation | Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.Contact us for customized product form or formulation. |
|---|
| Species | Human |
|---|
| Calculated MW | 15.11 kDa |
|---|
Background
Heparin-binding EGF-like growth factor (HB-EGF) is a 12-16 kDa member of the epidermal growth factor (EGF)family. It possesses an EGF-like domain, and a heparin-binding motif. Mature HB-EGF is a soluble peptide thatarises from proteolytic processing of the transmembrane form. Human HB -EGF shows 76% and 73% aasequence identity with rat and mouse HB-EGF, respectively. It is required for normal cardiac valve formationand normal heart function, promotes smooth muscle cell proliferation. It may be involved in macrophage-mediated cellular proliferation; it is mitogenic for fibroblasts, but not endothelial cells. HB-EGF classified as agroup 2 ErbB ligand based on its ability to activate both the EGF/ErbB1 and ErbB4 receptors. Activityassociated with ErbB4 binding appears to be limited to non -mitogenic actions, while EGFR binding inducesboth mitogenic and non-mitogenic activity.
Product information
| Synonym | DTR; DTS; DTSF; HEGFL; HBEGF; DTS; DTSF; HEGFL; HB-EGF |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | C-His |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
